Hans Petersen, president and CEO of Traversa, said: “The technology has received an outstanding level of interest for use with human therapeutics, and as a high throughput screening reagent, providing the company with both long-term growth prospects and a short-term revenue stream to augment this financing. Traversa is currently being evaluated by several large pharmaceutical companies to treat diseases of the eye and nose, metabolic diseases, cancer and infectious diseases.”